Katelyn J. Creasman

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

Marc E. Lenburg, Gordon B. Mills, James W. Smyth, 2012, The Journal of experimental medicine.

CDK1 Inhibition Targets the p53-NOXA-MCL1 Axis, Selectively Kills Embryonic Stem Cells, and Prevents Teratoma Formation

Robert L. Judson, Robert L Judson, K. Evason, 2015, Stem cell reports.

Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways

Karl A. Merrick, Chao Zhang, K. Shokat, 2012, Proceedings of the National Academy of Sciences.

Abstract S5-4: Synthetic-Lethality of Triple-Negative Breast Cancers Via the MYC Oncogene Pathway

G. Mills, M. Lenburg, A. Goga, 2010 .